Clinical Trial Update: PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients [Phase 1]

View source ↗

Summary

A Pfizer-sponsored Phase 1 trial evaluated oral CI-1033 in combination with paclitaxel and carboplatin as first-line therapy for non-small cell lung cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CI-1033
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small Cell Lung | Phase 1 | Status: COMPLETED